A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Clinical trial NCT02970318 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02970318
- Sponsor
- Acerta Pharma BV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-02
- Primary completion
- 2021-09-03
- Enrollment
- 310
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.